Abstract

One of the great challenges of cancermedicine is to develop effective treatments for bonemetastatic cancer.Most patients with advanced solid tumorswill develop bone metastasis andwill suffer fromskeletal related events associated with this disease. Although some therapies are available to manage symptoms derived from bone metastases, an effective treatment has not been developed yet. The mammalian target of rapamycin (mTOR) pathway regulates cell growth and survival. Alterations in mTOR signaling have been associated with pathological malignancies, including bone metastatic cancer. Inhibition of mTOR signalingmight therefore be a promising alternative for bonemetastatic cancermanagement. This review summarizes the current knowledge onmTOR pathway signaling in bone tissue and provides an overview on the known effects of mTOR inhibition in bone cancer, both in in vitro and in vivo models.

Autore Pugliese

• Silvestris Francesco

Tutti gli autori

• SILVESTRIS F.

Titolo volume/Rivista

Non Disponibile

Anno di pubblicazione

2014

ISSN

0304-419X

ISBN

Non Disponibile

Numero di citazioni Wos

13

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

13

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile